Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Tracking Still Possible With Shared Medicare Codes, Woodcock Suggests

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA and CMS are working on a way to address pharmacovigilance through code modifiers, CDER director tells Senate panel.


Related Content

FDA Biosimilar Education Campaign Will Need To Be Targeted